Publications by authors named "Raquel Binder"

Article Synopsis
  • COVID-19 had a significant impact on minority communities, highlighting the need for better research engagement with these groups, while existing evaluation methods hinder comprehensive analysis.
  • A cross-sectional study in Massachusetts showed that 91.4% of 290 participants had received a COVID-19 vaccine, and 41.7% reported past infections, with findings indicating varying antibody responses and lingering symptoms, particularly among middle-aged Latinas.
  • The study emphasized the importance of using saliva samples for serology and introduced standardized methods for better future evaluations, enhancing the understanding of COVID-19 and public health responses in underserved populations.
View Article and Find Full Text PDF

COVID-19 disproportionately affected minorities, while research barriers to engage underserved communities persist. Serological studies reveal infection and vaccination histories within these communities, however lack of consensus on downstream evaluation methods impede meta-analyses and dampen the broader public health impact. To reveal the impact of COVID-19 and vaccine uptake among diverse communities and to develop rigorous serological downstream evaluation methods, we engaged racial and ethnic minorities in Massachusetts in a cross-sectional study (April - July 2022), screened blood and saliva for SARS-CoV-2 and human endemic coronavirus (hCoV) antibodies by bead-based multiplex assay and point-of-care (POC) test and developed across-plate normalization and classification boundary methods for optimal qualitative serological assessments.

View Article and Find Full Text PDF

Herein, we review established clinical use cases for SARS-CoV-2 antibody measures, which include diagnosis of recent prior infection, isolating high titer convalescent plasma, diagnosing multisystem inflammatory syndrome in children (MIS-C), and booster dosing in the immunosuppressed and other populations. We then address whether an antibody correlate of protection (CoP) for SARS-CoV-2 has been successfully defined with the following considerations: Antibody responses in the immunocompetent, vaccine type, variants, use of binding antibody tests vs. neutralization tests, and endpoint measures.

View Article and Find Full Text PDF
Article Synopsis
  • The objective of the study was to investigate the demographic differences between pregnant individuals with COVID-19 who agreed to participate in research versus those who declined, focusing on the impact of SARS-CoV-2 on maternal health outcomes, especially in minority and low-income populations.
  • The methods included a secondary analysis of demographic data from a single hospital, utilizing electronic medical records and Chi-square testing to compare characteristics like race, ethnicity, primary language, and insurance type among those who participated and those who did not.
  • The results showed that out of 158 approached pregnant patients with COVID-19, 89 consented to participate while 69 declined, indicating a need to address disparities in research participation among different demographic groups.
View Article and Find Full Text PDF

Background: Evaluating the performance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological assays and clearly articulating the utility of selected antigens, isotypes, and thresholds is crucial to understanding the prevalence of infection within selected communities.

Methods: This cross-sectional study, implemented in 2020, screened PCRconfirmed coronavirus disease 2019 patients (n 86), banked prepandemic and negative samples (n 96), healthcare workers and family members (n 552), and university employees (n 327) for antiSARS-CoV-2 receptor-binding domain, trimeric spike protein, and nucleocapsid protein immunoglobulin (Ig)G and IgA antibodies with a laboratory-developed enzyme-linked immunosorbent assay and tested how antigen, isotype and threshold choices affected the seroprevalence outcomes. The following threshold methods were evaluated: (i) mean 3 standard deviations of the negative controls; (ii) 100 specificity for each antigen-isotype combination; and (iii) the maximal Youden index.

View Article and Find Full Text PDF

Background: Global efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and long-term sequelae, as well as immune responses after vaccination across populations and the social dimensions of prevention and treatment strategies.

Methods: In the United States, the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation's largest coordinated effort to study coronavirus disease 2019. The network comprises multidisciplinary researchers bridging gaps and fostering collaborations among immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policymakers, data scientists, and community members.

View Article and Find Full Text PDF
Article Synopsis
  • The National Cancer Institute established the Serological Sciences Network (SeroNet) in October 2020 to study immune responses to COVID-19 and enhance serological testing technologies.
  • SeroNet involves 25 research institutions collaborating on COVID-19 serological assays, including developing and sharing assay procedures and harmonization plans.
  • A structured approach was taken to calibrate various serological assays to reference standards, resulting in a wide range of developed assays that will allow for consistent reporting and future data comparisons across studies.
View Article and Find Full Text PDF

Since the beginning of the SARS-CoV-2 pandemic, antibody responses and antibody effector functions targeting SARS-CoV-2-infected cells have been understudied. Consequently, the role of these types of antibodies in SARS-CoV-2 disease (COVID-19) and immunity is still undetermined. To provide tools to study these responses, we used plasma from SARS-CoV-2-infected individuals (n = 50) and SARS-CoV-2 naive healthy controls (n = 20) to develop four specific and reproducible flow cytometry-based assays: (i) two assessing antibody binding to, and antibody-mediated NK cell degranulation against, SARS-CoV-2-infected cells and (ii) two assessing antibody binding to, and antibody-mediated NK cell degranulation against, SARS-CoV-2 Spike-transfected cells.

View Article and Find Full Text PDF
Article Synopsis
  • - In October 2020, the National Cancer Institute launched the Serological Sciences Network (SeroNet) to research the immune response to COVID-19 and improve serological testing through collaboration among 25 research institutions.
  • - A detailed survey was conducted to gather information on various COVID-19 serological assays, while a protocol was established to calibrate these assays to reference standards for better data comparison.
  • - SeroNet institutions developed multiple COVID-19 serological assay methods and standardized calibration protocols, which will enhance the accuracy and comparability of future studies on SARS-CoV-2 and vaccine responses.
View Article and Find Full Text PDF

We assessed environmental contamination of inpatient rooms housing coronavirus disease 2019 (COVID-19) patients in a dedicated COVID-19 unit. Contamination with severe acute respiratory syndrome coronavirus 2 was found on 5.5% (19/347) of surfaces via reverse transcriptase polymerase chain reaction and 0.

View Article and Find Full Text PDF

Background: Leptospirosis diagnoses have increased in Sarawak, Malaysia in recent years.

Methods: To better understand the burden of disease and associated risk factors, we evaluated 147 patients presenting with clinical leptospirosis to local hospitals in Sarawak, Malaysia for the presence of Leptospira and associated antibodies. Sera and urine specimens collected during the acute illness phase were assessed via a commercially available rapid diagnostic test (Leptorapide, Linnodee Ltd.

View Article and Find Full Text PDF

Background: Nicaragua experienced a large Zika epidemic in 2016, with up to 50% of the population in Managua infected. With the domesticated Aedes aegypti mosquito as its vector, it is widely assumed that Zika virus transmission occurs within the household and/or via human mobility. We investigated these assumptions by using viral genomes to trace Zika transmission spatially.

View Article and Find Full Text PDF

Dengue virus serotypes 1 to 4 (DENV1–4) and Zika virus (ZIKV) are mosquito-borne flaviviruses that induce both virus-specific and broadly reactive antibodies. A first DENV infection is thought to induce antibodies that wane over 2 years to titers that can subsequently enhance severe dengue disease. Secondary DENV infection with a different serotype is thought to induce stable, cross-serotype protective antibodies.

View Article and Find Full Text PDF

We examined a collection of 386 animal, 451 human, and 109 archived bioaerosol samples with a new pan-species coronavirus molecular assay. Thirty-eight (4.02%) of 946 specimens yielded evidence of human or animal coronaviruses.

View Article and Find Full Text PDF
Article Synopsis
  • - Antiviral therapies target viruses but face challenges due to viral mutations; thus, researchers are exploring ways to target host proteins that viruses use for replication.
  • - A study focusing on the alphacoronavirus HCoV-229E identified TMEM41B, an essential host protein, which is crucial for the lifecycle of multiple coronaviruses, including SARS-CoV-2.
  • - TMEM41B is needed early in the viral replication process and may aid in forming viral replication complexes by helping manage lipids and membrane dynamics, suggesting it could be a target for developing new antiviral therapies.
View Article and Find Full Text PDF

Human adenovirus type 4 (HAdV-E4) frequently causes epidemics among military and civilian populations. We conducted a systematic review of 144 peer-reviewed articles reporting HAdV-E4 infections, published during the years 1960-2020. More than 24 500 HAdV-E4 infections, including 27 associated deaths, were documented.

View Article and Find Full Text PDF

During April and May 2020, we studied 20 patients hospitalized with coronavirus disease 2019 (COVID-19), their hospital rooms (fomites and aerosols), and their close contacts for molecular and culture evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Among >400 samples, we found molecular evidence of virus in most sample types, especially the nasopharyngeal (NP), saliva, and fecal samples, but the prevalence of molecular positivity among fomites and aerosols was low. The agreement between NP swab and saliva positivity was high (89.

View Article and Find Full Text PDF

Background: During the past two decades, three novel coronaviruses (CoVs) have emerged to cause international human epidemics with severe morbidity. CoVs have also emerged to cause severe epidemics in animals. A better understanding of the natural hosts and genetic diversity of CoVs are needed to help mitigate these threats.

View Article and Find Full Text PDF